IL-CULLIGAN
Culligan International (“Culligan”), the innovative brand in consumer-focused, sustainable water solutions and services, and Waterlogic Group Holdings (“Waterlogic”), a global designer, manufacturer, distributor and service provider of purified drinking water dispensers, announced today the completion of their transaction to combine, creating a leader in clean and sustainable drinking water solutions and services. Headquartered in Rosemont, Illinois, the combined company operates under the Culligan name.
With over 11,000 employees operating directly in 30 countries, Culligan generates combined annual revenues of about $2.4 billion and is well-positioned to expand in the fast-growing $35 billion global consumer water market. The combination diversifies the company’s product range and increases its global reach, including an expansive dealer network in more than 70 countries. It brings additional scale and expertise to drive innovation in the development of new household and commercial water filtration, purification and treatment solutions, expanding those to both existing and new markets, and it bolsters distribution channels across the Americas, Europe, the Middle East, Africa and Asia Pacific.
“Our two organizations make a powerful combined team as one Culligan, aligned on values and committed to a clear purpose to change people’s lives and to improve the environment,” said Scott Clawson, President and CEO of Culligan International. “Culligan is a leading global consumer water solutions and services provider whose mission is to deliver clean, safe and soft water to improve consumers’ health and wellness and reduce single-use plastics. Serving over 100 million people globally, our solutions save more than 40 billion plastic bottles annually.”
“Our deep, mutual belief that we have the ability and responsibility to contribute positively to the Earth guides our decisions and is engrained in our operations,” said Jeremy Ben-David, founder and former Group CEO of Waterlogic who now serves Culligan as CEO of the Europe, Middle East and Africa region, and a member of the Executive Leadership of Culligan Global. “We take to heart the United Nations Sustainable Development Goals, and today we are aligned to make an even more positive impact in all we do.”
The combined company is majority owned by funds affiliated with BDT Capital Partners, LLC (“BDT”) and by the firm’s co-investors. In 2021, funds managed by BDT, an affiliate of BDT & Company, LLC, a merchant bank that works with family- and founder-led businesses to pursue their strategic and financial objectives, acquired Culligan alongside a group of strategic family business owners and investors within the firm’s global network. Waterlogic was acquired in January 2015 by funds managed by Castik Capital, a European private equity investor, which alongside former Waterlogic management team members and other shareholders, has a meaningful minority ownership position in Culligan.
Terms of the transaction were not disclosed.
About Culligan International
Founded in 1936 and headquartered in Rosemont, Illinois, Culligan International makes a real difference to people’s lives by providing clean, safe, great-tasting water to more than 100 million consumers globally. With over 11,000 employees in 30 countries, we generate combined annual revenues of about $2.4 billion and are well-positioned to expand in the $35 billion global consumer water market. Culligan is one of the world’s most-recognized and trusted names in water, a reputation built through an 85-year legacy of trust, innovation, service and quality. The Culligan master brand covers a family of iconic brands and innovative technologies that include Quench, Blupura, Zip Water, Purezza Premium Water and Firewall® UVC purification. Our combination with Waterlogic diversifies our product range and increases our global reach, including through an expansive dealer network in over 70 countries. It helps bring a breadth of household, commercial and retail solutions to new markets and distribution channels across the Americas, Europe, the Middle East, Africa and Asia Pacific. As a purpose-led business, we strive to reduce the environmental impact across the supply chain, and we save more than 40 billion plastic bottles annually through our sustainable water filtration, purification and treatment solutions. For more information visit: www.corporate.culligan.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221101006416/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coulson Aviation Announces Launch of Boeing 767 VLAT Program22.12.2025 14:03:00 CET | Press release
Advancing the Next Generation of High-Capacity Aerial Firefighting Coulson Aviation USA has announced the launch of its Boeing 767 Very Large Airtanker (VLAT) program, marking a significant advancement in the evolution of aerial firefighting capability. The program is intended to provide a sustainable replacement for legacy VLAT platforms nearing the end of their operational service life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251222917730/en/ A cross-sectional view of Coulson Aviation’s Boeing 767 Very Large Airtanker (VLAT) illustrates the integration of the RADS retardant delivery system and the next generation of high-capacity, sustainable aerial firefighting design. The recent grounding of the MD11 and DC10 fleets has highlighted a structural challenge for firefighting agencies worldwide. As older widebody aircraft are retired, the industry faces a significant reduction in high-capacity, large-scale retardant de
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom